Cowen Remains Bullish After Meeting with Spark Therapeutics (ONCE)

Cowen reiterated an Outperform rating and $70.00 price target on Spark Therapeutics (NASDAQ: ONCE) after meeting with management. There was much investor interest in Spark following the release of impressive Ph. II and III data over the last several weeks. Discussions were broad, ranging over topics such as the data, SPK-RPE65's label, gene therapy reimbursement strategies, and the status of Spark's earlier pipeline programs.

Analyst Phil Nadeau commented, "Earlier this week we hosted Spark management in New York. With impressive Ph. II and III data in hand, we view SPK-RPE65 as a significantly de-risked asset. Management appears very confident in its ability to secure a wide label, and is open to discussing novel reimbursement models with payors. SPK-CHM and SPK-FIX are progressing. We continue to think ONCE is undervalued."

For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.

Shares of Spark Therapeutics closed at $55.94 yesterday.

You May Also Be Interested In

• Affirm Holdings (AFRM) PT Raised to $124 at TD Cowen
• Affirm Holdings (AFRM) PT Raised to $101 at BMO Capital
• Dollar General (DG) PT Raised to $123 at Piper Sandler